. 2023 Jul 19;20(1):112–123. doi: 10.1002/alz.13381

TABLE 5.

Characteristics and test scores for case–control matched cognitively normal participant true controls versus preclinical AD.

		Case–control matched cognitively normal participants with CSF biomarker data
		True controls (biomarker negative, n = 26)		Preclinical AD (biomarker positive, n = 26)
Type of characteristic	Demographic/measure	M	SD	M	SD
Demographic	Age	78.7^a	4.8	80.0^a	6.2
	Education	17.8^a	2.1	17.1^a	1.6
	Male/female	13/13		13/13
Cognitive status	MMSE	28.7^a	1.5	28.8^a	1.4
	MoCA	25.4^a	2.2	25.3^a	2.7
	DRS	138.7^a	3.7	138.0^a	4.8
CSF biomarker	Tau/Aβ42	.3^a	0.1	1.4^b	2.0
	Tau	300.9^a	150.6	576.0^b	235.4
	Aβ42	1006.5^a	473.2	534.2^b	182.2
	CSF to cognitive test lag (years)	2.5^a	1.5	3.4^a	3.1
Existing naming test	32‐item MINT	31.2^a	1.0	30.6^a	1.8
MINT Sprint scores	First pass correct	74.3^a	3.8	72.7^a	5.4
	Second pass correct	4.0^a	2.2	4.0^a	2.7
	Total correct	78.3 ^a	2.0	76.7 ^b	3.5
	Percent resolved (PR)	75.6 ^a	18.5	62.4 ^b	25.4
	Efficiency first pass	2.0^a	0.6	2.1^a	0.4
	Efficiency total	3.1^a	1.4	3.6^a	1.2
	Minutes first pass	2.2^a	0.8	2.3^a	0.6
	Minutes total	3.2^a	1.5	3.8^a	1.5

Note: Values in the same row that do not share the same superscript are significantly different at p < 0.05 (2‐tailed). Significant differences between groups highlighted in bold. Efficiency = completion time/percent correct.

Abbreviations: Aβ, amyloid beta; AD, Alzheimer's disease; CSF, cerebrospinal fluid; DRS, Dementia Rating Scale; MCI, mild cognitive impairment; MINT, Multilingual Naming Test; MMSE, Mini‐Mental State Examination; MoCA, Montreal Cognitive Assessment; SD, standard deviation.